{"id":1459,"date":"2026-05-26T08:16:42","date_gmt":"2026-05-26T13:16:42","guid":{"rendered":"https:\/\/elyxaminos.com\/producto\/ss-31-50mg\/"},"modified":"2026-07-27T09:32:48","modified_gmt":"2026-07-27T14:32:48","slug":"ss-31-50mg","status":"publish","type":"product","link":"https:\/\/elyxaminos.com\/en\/producto\/ss-31-50mg\/","title":{"rendered":"SS-31 50mg"},"content":{"rendered":"<section>\n<h2>SS-31 50mg<\/h2>\n<p><strong>Tetrapeptide cardiolipin \u00b7 Mitochondrial function \u00b7 Research Only<\/strong><\/p>\n<h3>What is it and how does it work?<\/h3>\n<p>SS-31 (Elamipretide \/ MTP-131 \/ Bendavia) is an aromatic-cationic tetrapeptide (D-Arg-DMT-Lys-Phe-NH2) developed by Szeto and Schiller. Mechanistic literature documents that it crosses the outer mitochondrial membrane and selectively binds to cardiolipin in the inner membrane (Szeto HH, Br J Pharmacol 2014, PMID 23647488), with stabilization of respiratory chain supercomplexes (I, III, IV), preservation of ATP synthase, reduction of electron leak, and decrease in ROS without collapse of the \u0394\u03a8m potential in experimental models.<\/p>\n<p>Clinical research evidence: Karaa et al. (Neurology 2018, PMID 30568002) in primary mitochondrial myopathy. Daubert et al. (Circ Heart Fail 2017, PMID 29217757) in exploratory heart failure. Stealth BioTherapeutics trial program \u2014 PROGRESS-HF, MMPOWER-3, TAZPOWER (Barth syndrome), ReCLAIM (dry AMD\/geographic atrophy) \u2014 validated SubQ 40 mg\/day safety in research with positive signals on secondary endpoints. Research material only \u2014 no FDA-approved human use.<\/p>\n<h3>Reconstitution and dosage<\/h3>\n<ul>\n<li><strong>Vial<\/strong> 50 mg lyophilized<\/li>\n<li><strong>Bacteriostatic water:<\/strong> 2 ml (tablet \u2014 standard rule would be 10 ml, doesn't fit in 3ml vial)<\/li>\n<li><strong>Resulting concentration:<\/strong> 25,000 mcg\/ml = 25 mg\/ml<\/li>\n<li><strong>Per unit U-100:<\/strong> 250 mcg \u00b7 verification: 25,000 \u00f7 100 = 250 mcg\/u \u2713<\/li>\n<li><strong>Conservation<\/strong> Refrigerated 2\u20138\u00b0C \u00b7 Use within 28\u201330 days \u00b7 Protect from light (photosensitive) \u00b7 DO NOT FREEZE reconstituted<\/li>\n<li><strong>Performance<\/strong> Equivalent volume: 200 U-100 units per reconstituted vial<\/li>\n<\/ul>\n<h3>Volume Conversion Chart (U-100 syringe)<\/h3>\n<table border=\"1\" cellpadding=\"6\" cellspacing=\"0\" style=\"border-collapse: collapse;width: 100%\">\n<thead>\n<tr>\n<th style=\"background-color: #02042B;color: white;padding: 8px\">U-100 equivalent<\/th>\n<th style=\"background-color: #02042B;color: white;padding: 8px\">Volume<\/th>\n<th style=\"background-color: #02042B;color: white;padding: 8px\">Charge<\/th>\n<th style=\"background-color: #02042B;color: white;padding: 8px\">Verification<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 6px\">20 u<\/td>\n<td style=\"padding: 6px\">0.20 mL<\/td>\n<td style=\"padding: 6px\">5,000 mcg (5 mg)<\/td>\n<td style=\"padding: 6px\">20 units \u00d7 250 mcg = 5,000 mcg<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 6px\">40 years old<\/td>\n<td style=\"padding: 6px\">0.40 mL<\/td>\n<td style=\"padding: 6px\">10,000 mcg (10 mg)<\/td>\n<td style=\"padding: 6px\">40 u x 250 mcg = 10,000 mcg<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 6px\">80 u<\/td>\n<td style=\"padding: 6px\">0.80 ml<\/td>\n<td style=\"padding: 6px\">20,000 mcg (20 mg)<\/td>\n<td style=\"padding: 6px\">80 IU \u00d7 250 mcg = 20,000 mcg<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 6px\">160 u<\/td>\n<td style=\"padding: 6px\">1.60 ml<\/td>\n<td style=\"padding: 6px\">40,000 mcg (40 mg)<\/td>\n<td style=\"padding: 6px\">160 u \u00d7 250 mcg = 40,000 mcg \u2713 (Stealth Phase III dose)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Documented evidence in research literature<\/h3>\n<details>\n<summary><strong>Clinical research evidence \u00b7 cardiomyopathy and mitochondrial myopathy<\/strong><\/summary>\n<ul>\n<li>Stealth BioTherapeutics \u2014 PROGRESS-HF (HFrEF), MMPOWER-3 (primary mitochondrial myopathy), and TAZPOWER (Barth syndrome) trials used 40 mg\/day SubQ investigational<\/li>\n<li>Karaa et al., Neurology 2018 (PMID 30568002) \u2014 Primary mitochondrial myopathy, improvement reported in 6MWT<\/li>\n<li>Daubert et al., Circ Heart Fail 2017 (PMID 29217757) \u2014 acute improvement in diastolic function in HFrEF under investigation<\/li>\n<li>MMPOWER-3 and EMBRACE-DMD: primary endpoints not met but improvement in secondary functional markers confirmed<\/li>\n<\/ul>\n<\/details>\n<details>\n<summary><strong>Clinical research evidence \u00b7 macular degeneration<\/strong><\/summary>\n<ul>\n<li>Stealth RECLAIM and RECLAIM-2 \u2014 research in dry AMD \/ geographic atrophy with 40 mg\/day SubQ administration<\/li>\n<li>Positive signals reported in secondary visual functional markers<\/li>\n<\/ul>\n<\/details>\n<details>\n<summary><strong>Documented molecular mechanism<\/strong><\/summary>\n<ul>\n<li>Szeto HH, Br J Pharmacol 2014 (PMID 23647488) \u2014 selective binding to mitochondrial cardiolipin<\/li>\n<li>Reported stabilization of respiratory chain supercomplexes I, III, IV<\/li>\n<li>Documented reduction of electron leakage and ROS without collapse of \u0394\u03a8m<\/li>\n<li>Restoration of ATP synthase in models of mitochondrial dysfunction<\/li>\n<\/ul>\n<\/details>\n<h3>Combinations reported in literature<\/h3>\n<ul>\n<li>SS-31 + MOTS-C: Complementary Mitochondrial Mechanisms in the Literature \u2014 MOTS-C Metabolic Signaling (AMPK) + SS-31 Mitochondrial Structural Preservation.<\/li>\n<li>SS-31 + NAD+ (injectable or oral NMN\/NR): Literature reports complementarity \u2014 NAD+ substrate of complex I\/sirtuins; SS-31 protects mitochondrial machinery.<\/li>\n<li>SS-31 + Urolithin A oral: Emerging Literature \u2014 Urolithin Induces Mitophagy (Replacement of Damaged Mitochondria); SS-31 Protects Functional Ones.<\/li>\n<li>SS-31 + CJC\/Ipamorelin: Literature reports independent axes \u2014 GH\/IGF-1 (tissue recovery) + SS-31 (mitochondrial oxidative capacity).<\/li>\n<\/ul>\n<h3>Practical notes<\/h3>\n<ul>\n<li>Via documented in primary research literature: SubQ. Stealth BioTherapeutics validated SubQ 40 mg\/day in all phase III trials. Large peptide (640 Da) highly cationic \u2014 not absorbed orally\/sublingually\/intranasally at comparable doses.<\/li>\n<li>Reconstitution compressed to 2 ml (standard rule would give 10 ml, does not fit in 3 ml vial). Concentration 250 mcg\/u \u2014 mental scale equivalent to GHK-Cu.<\/li>\n<li>Response window documented in clinical literature: functional markers (6MWT, VO2, subjective energy) at weeks 4-8. Structural markers (echo, GLS) require 12+ weeks.<\/li>\n<\/ul>\n<h3>Contraindications and precautions<\/h3>\n<ul>\n<li>For research use only. Not approved by the FDA for human use. The literature documents local reactions (erythema, pruritus, induration) in ~30\u201350% of subjects receiving 40 mg\/day in the MMPOWER-3 and ReCLAIM studies. Not for human use. Do not mix in the same syringe with anionic peptides (Thymosin Beta-4)\u2014precipitation has been reported in the literature.<\/li>\n<\/ul>\n<p><em><strong>Research material only. Not approved for human use by the FDA.<\/strong> This product is intended for scientific research purposes in controlled laboratory settings only. It is not a drug. Not for human or animal administration, therapeutic use, or diagnostic use.<\/em><\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"<p><strong>Tetrapeptide cardiolipin \u00b7 Mitochondrial function \u00b7 Research Only<\/strong><\/p>\n<ul>\n<li>SS-31 (Elamipretide \/ MTP-131 \/ Bendavia) is an aromatic-cationic tetrapeptide (D-Arg-DMT-Lys-Phe-NH2) developed by Szeto and Schiller.<\/li>\n<li>Mechanistic literature documents that it crosses the outer mitochondrial membrane and selectively binds to cardiolipin in the inner membrane (Szeto HH, Br J Pharmacol 2014, PMID 23647488), with stabilization of respiratory chain supercomplexes (I, III, IV), preservation of ATP synthase, reduction of electron leak, and decreased ROS without collapse of the \u0394\u03a8m potential in experimental models.<\/li>\n<li><strong>Presentation<\/strong> 50 mg lyophilized lyophilized \u00b7 <strong>For research purposes only<\/strong><\/li>\n<\/ul>\n<p><!-- ELYX-CERT-BUTTONS:start --><\/p>\n<div style=\"display: flex;flex-wrap: wrap;gap: 8px;justify-content: center;margin-top: 16px;margin-bottom: 8px\">\n<a href=\"https:\/\/elyxaminos.com\/wp-content\/uploads\/2026\/05\/SS31_50MG_COA.pdf\" target=\"_blank\" rel=\"noreferrer\"><button style=\"display: flex;align-items: center;justify-content: center;background: linear-gradient(264.62deg, #02042B 11.77%, #0334D8 62.3%, #48DFE4 91.88%);padding: 12px 24px;border-radius: 50px;color: white;border: none;font-weight: bold;cursor: pointer;text-align: center;font-family: sans-serif;min-width: 130px\">Certificate of Analysis<\/button><\/a><br \/>\n<a href=\"https:\/\/elyxaminos.com\/wp-content\/uploads\/2026\/05\/SS31_50MG_ENDO.pdf\" target=\"_blank\" rel=\"noreferrer\"><button style=\"display: flex;align-items: center;justify-content: center;background: linear-gradient(264.62deg, #02042B 11.77%, #0334D8 62.3%, #48DFE4 91.88%);padding: 12px 24px;border-radius: 50px;color: white;border: none;font-weight: bold;cursor: pointer;text-align: center;font-family: sans-serif;min-width: 130px\">Endotoxins<\/button><\/a>\n<\/div>\n<p><!-- ELYX-CERT-BUTTONS:end --><\/p>","protected":false},"featured_media":1590,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[39],"product_tag":[],"class_list":{"0":"post-1459","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-aging","8":"first","9":"instock","10":"shipping-taxable","11":"purchasable","12":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product\/1459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/comments?post=1459"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/media\/1590"}],"wp:attachment":[{"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/media?parent=1459"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product_brand?post=1459"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product_cat?post=1459"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/elyxaminos.com\/en\/wp-json\/wp\/v2\/product_tag?post=1459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}